Publications by authors named "Ji-Hao Shi"
World J Gastroenterol
November 2020
Article Synopsis
- Infliximab is the first biologic treatment for moderate to severe Crohn's disease (MS-CD) in China, and its cost-effectiveness compared to conventional therapy was unclear.
- A study assessed the cost-effectiveness of infliximab maintenance therapy (IMT) for MS-CD patients in China, finding that IMT led to better health outcomes and lower overall costs than conventional maintenance therapy (CMT).
- The findings suggest that IMT is a cost-effective option for treating MS-CD, costing under one GDP per capita to gain a quality-adjusted life year (QALY), with a strong likelihood of being cost-effective for health insurers.
